

Daniel Aletaha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8190186/publications.pdf>

Version: 2024-02-01

248
papers

44,057
citations

11235

73
h-index

2453

203
g-index

257
all docs

257
docs citations

257
times ranked

26705
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Comment on "Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab" by Pethoe-Schramm et al". Annals of the Rheumatic Diseases, 2022, 81, e137-e137.	0.5	0
2	Response to: "Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis" by Bugatti et al". Annals of the Rheumatic Diseases, 2022, 81, e56-e56.	0.5	1
3	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 20-33.	0.5	104
4	Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. Annals of the Rheumatic Diseases, 2022, 81, 175-183.	0.5	6
5	Baseline predictors of different types of treatment success in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 153-158.	0.5	6
6	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology, 2022, 61, 2815-2825.	0.9	12
7	Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. Annals of the Rheumatic Diseases, 2022, 81, 416-421.	0.5	19
8	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight Joint Disease Activity Score, C-reactive Protein Level, and Patient Global Assessment. Arthritis Care and Research, 2022, 74, 1-5.	1.5	3
9	Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?. Annals of the Rheumatic Diseases, 2022, 81, 7-10.	0.5	15
10	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight Joint Disease Activity Score, C-reactive Protein Level, and Patient Global Assessment. Arthritis and Rheumatology, 2022, 74, 5-9.	2.9	4
11	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, C-reactive Protein, and Patient Global Assessment. ACR Open Rheumatology, 2022, 4, 123-127.	0.9	5
12	Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. Annals of the Rheumatic Diseases, 2022, 81, 4-7.	0.5	7
13	Reply. Arthritis Care and Research, 2022, 74, 502-503.	1.5	0
14	Reply. ACR Open Rheumatology, 2022, 4, 269-270.	0.9	0
15	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. Annals of the Rheumatic Diseases, 2022, 81, 601-613.	0.5	31
16	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 687-694.	0.5	43
17	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 622-631.	0.5	4
18	The undifferentiated arthritis dilemma: the story continues. Nature Reviews Rheumatology, 2022, 18, 189-190.	3.5	1

#	ARTICLE	IF	CITATIONS
19	Response to: Correspondence on "Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment"™ by Felson <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2021-221941.	0.5	0
20	Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 838-844.	0.5	41
21	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp>/<scp>PRAAS</scp>, <scp>SAVI</scp>, and <scp>AGS</scp>. <i>Arthritis and Rheumatology</i> , 2022, 74, 735-751.	2.9	23
22	TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. <i>Rheumatology</i> , 2022, 61, 4535-4546.	0.9	9
23	Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1017-1022.	0.5	14
24	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. <i>RMD Open</i> , 2022, 8, e002099.	1.8	12
25	Reflections on a contemporary European tragedy. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 747-748.	0.5	2
26	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. <i>Arthritis and Rheumatology</i> , 2022, 74, 716-721.	2.9	14
27	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 907-921.	0.5	38
28	Standardisation of ACPA tests: evaluation of a new candidate reference preparation. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1379-1384.	0.5	2
29	Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1374-1378.	0.5	6
30	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1203-1205.	0.5	4
31	Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211059.	1.2	5
32	Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. <i>Bone and Joint Research</i> , 2022, 11, 484-493.	1.3	3
33	IgA rheumatoid factor in rheumatoid arthritis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1617-1626.	1.4	6
34	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.5	158
35	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.5	224
36	Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 682-691.	0.9	7

#	ARTICLE	IF	CITATIONS
37	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	1.2	8
38	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021, 7, e001465.	1.8	9
39	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 884-890.	0.5	28
40	P178 The impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis. <i>Rheumatology</i> , 2021, 60, .	0.9	0
41	SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1355-1356.	0.5	116
42	Response to: "Correspondence on "Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis" by Dumoulin et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrhumdis-2021-220922.	0.5	1
43	Response to: "Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Westhoff et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e163-e163.	0.5	4
44	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	2.5	12
45	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1345-1350.	0.5	211
46	Can imaging help unravel pain in psoriatic arthritis?. <i>Rheumatology</i> , 2021, , .	0.9	0
47	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1286-1298.	0.5	31
48	Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021, 7, e001621.	1.8	10
49	Message from the new EULAR President and Steering Group. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1266-1267.	0.5	0
50	Response to: "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e167-e167.	0.5	4
51	SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1249-1251.	0.5	6
52	A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001768.	1.8	14
53	In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. <i>RMD Open</i> , 2021, 7, e001737.	1.8	4
54	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1519-1534.	1.1	42

#	ARTICLE	IF	CITATIONS
55	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.5	30
56	Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221160.	0.5	11
57	Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eightâ€“joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>RMD Open</i> , 2021, 7, e002034.	1.8	7
58	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. <i>RMD Open</i> , 2021, 7, e001962.	1.8	1
59	Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. <i>RMD Open</i> , 2021, 7, e002038.	1.8	3
60	The slippery road of adherence in chronically ill individuals. <i>Rheumatology</i> , 2020, 59, 9-11.	0.9	0
61	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	1.6	25
62	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 245-251.	1.6	20
63	Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 324-334.	0.9	29
64	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020, 59, 1556-1565.	0.9	9
65	Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , 2020, 108, 102379.	3.0	31
66	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	0.9	13
67	A critical review of the reproductive safety of Leflunomide. <i>Clinical Rheumatology</i> , 2020, 39, 607-612.	1.0	8
68	P281â€“52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naïve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors. <i>Rheumatology</i> , 2020, 59, .	0.9	0
69	Genetic risk scores in inflammatory arthritis: a new era?. <i>Nature Reviews Rheumatology</i> , 2020, 16, 545-546.	3.5	3
70	Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. <i>Clinical Chemistry</i> , 2020, 66, 1405-1413.	1.5	122
71	Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 874-882.	0.5	16
72	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 700.1-712.	0.5	609

#	ARTICLE	IF	CITATIONS
73	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233781.	1.1	32
74	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. Seminars in Arthritis and Rheumatism, 2020, 50, 643-644.	1.6	6
75	<p>Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study</p>. Patient Preference and Adherence, 2020, Volume 14, 949-961.	0.8	10
76	Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?. Lancet, The, 2020, 395, 1091-1093.	6.3	0
77	Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093348.	1.2	1
78	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. Annals of the Rheumatic Diseases, 2020, 79, 445-452.	0.5	42
79	Precision medicine and management of rheumatoid arthritis. Journal of Autoimmunity, 2020, 110, 102405.	3.0	56
80	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.5	1,860
81	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis and Rheumatology, 2020, 72, 1227-1229.	2.9	1
82	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. Nature Medicine, 2020, 26, 974-980.	15.2	9
83	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. RMD Open, 2020, 6, e001432.	1.8	23
84	Are we failing patients in our assessment of treatment failure?. Rheumatology, 2019, 58, 561-562.	0.9	4
85	To DAPSA or not to DAPSA? That is not the question. Annals of the Rheumatic Diseases, 2019, 78, e61-e61.	0.5	3
86	Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. Nature Reviews Rheumatology, 2019, 15, 633-634.	3.5	45
87	Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. PLoS ONE, 2019, 14, e0219698.	1.1	12
88	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324.	0.8	1
89	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. Arthritis Research and Therapy, 2019, 21, 231.	1.6	6
90	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. Rheumatology, 2019, 58, 2091-2098.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Achieving Clinical Remission for Patients With Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2019, 321, 457.	3.8	17
92	Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. Advances in Therapy, 2019, 36, 1672-1683.	1.3	34
93	Risk profiling for a refractory course of rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 2019, 49, 211-217.	1.6	62
94	AB0277â€¦EFFECT OF DISEASE DURATION AND OTHER PATIENT BASELINE CHARACTERISTICS ON OUTCOMES IN TOCILIZUMAB-TREATED RHEUMATOID ARTHRITIS PATIENTS: A POOLED ANALYSIS. , 2019, , .		0
95	SAT0160â€¦PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
96	SAT0104â€¦INITIAL EVIDENCE FOR THE NEED OF A DUAL TREAT-TO-TARGET STRATEGY IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
97	THU0431â€¦FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS. , 2019, , .		0
98	FRI0162â€¦BASELINE CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH ANAEMIA IN CLINICAL STUDIES OF TOFACITINIB IN RHEUMATOID ARTHRITIS. , 2019, , .		0
99	AB0417â€¦EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS. , 2019, , .		0
100	SAT0061â€¦IMPORTANT ROLE OF CD11C+ CELLS IN INFLAMMATORY ARTHRITIS. , 2019, , .		0
101	THU0133â€¦TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
102	Treating Rheumatic Diseases to Target: A Story of Success. Rheumatic Disease Clinics of North America, 2019, 45, xi-xii.	0.8	0
103	Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition. Journal of Clinical Medicine, 2019, 8, 2174.	1.0	3
104	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1609-1615.	0.5	33
105	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. Rheumatology, 2019, 58, 1025-1033.	0.9	13
106	Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. Annals of the Rheumatic Diseases, 2019, 78, e54-e54.	0.5	1
107	Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. Rheumatology, 2018, 57, 969-976.	0.9	4
108	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	18.1	1,441

#	ARTICLE	IF	CITATIONS
109	The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 311-313.	0.5	9
110	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.5	484
111	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	1.8	17
112	EULAR "points to consider"™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	1.8	16
113	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	1.8	9
114	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1736-1741.	0.5	30
115	Diagnosis and Management of Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1360.	3.8	1,257
116	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 401-414.	1.4	17
117	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.5	83
118	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , 2018, 36, 4875-4879.	1.7	37
119	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	1.6	18
120	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.5	393
121	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 960-977.	0.5	3,366
122	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.5	209
123	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet</i> , The, 2017, 389, 1206-1217.	6.3	94
124	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	2.9	39
125	Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 193-198.	1.6	14
126	08.28...The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
127	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045.	0.5	38
128	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	2.9	24
129	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , 2017, 69, 518-528.	2.9	23
130	Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor- α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 451-458.	0.7	8
131	The many faces of psoriatic arthritis – a challenge to treatment to target?. <i>Reumatologia</i> , 2016, 1, 1-2.	0.5	4
132	Therapeutic implications of autoantibodies in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000009.	1.8	39
133	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026.	1.0	6
134	Rheumatoid arthritis. <i>Lancet</i> , The, 2016, 388, 2023-2038.	6.3	2,989
135	Fever of unknown origin (FUO) revised. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 796-801.	1.0	54
136	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	0.9	22
137	An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 791-795.	1.0	30
138	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.5	275
139	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 3-15.	0.5	1,114
140	Management of rheumatoid arthritis: what happens and what does not happen in real life. <i>Rheumatology International</i> , 2016, 36, 167-168.	1.5	2
141	Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study. <i>Rheumatology</i> , 2016, 55, 41-48.	0.9	11
142	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818.	0.5	325
143	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.5	63
144	Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S45-S48.	0.4	7

#	ARTICLE	IF	CITATIONS
145	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203.	1.6	23
146	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 229.	1.6	73
147	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	0.9	51
148	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.5	223
149	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.5	10
150	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 3-9.	0.5	125
151	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	3.5	372
152	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	1.6	58
153	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.5	36
154	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	1.5	386
155	New insights into the measurement of disease activity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 268-272.	2.0	7
156	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67.	0.5	12
157	Evaluation and outcomes of patients with rheumatoid arthritis. , 2015, , 790-801.		2
158	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50.	0.4	30
159	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.5	11
160	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.5	212
161	Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imagingâ€“Detected Synovitis and Radiographic Progression. <i>Arthritis and Rheumatology</i> , 2014, 66, 794-802.	2.9	52
162	Reply. <i>Arthritis and Rheumatology</i> , 2014, 66, 3245-3246.	2.9	0

#	ARTICLE	IF	CITATIONS
163	Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature. <i>Journal of rheumatology Supplement, The</i> , 2014, 92, 9-14.	2.2	29
164	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.5	222
165	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	1.6	108
166	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 492-509.	0.5	1,688
167	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 114-123.	0.5	118
168	How FABulous is PEGgy? Certoliziumab Pegol from the Bench to the Patients. <i>BioDrugs</i> , 2014, 28, 3-4.	2.2	0
169	Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission. <i>Arthritis and Rheumatism</i> , 2013, 65, 2005-2014.	6.7	56
170	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6.	0.5	98
171	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 241-244.	0.5	44
172	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12.	0.5	24
173	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.5	114
174	Compression Test (Gaenslen's Squeeze Test) Positivity, Joint Tenderness, and Disease Activity in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 653-657.	1.5	16
175	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 875-880.	0.5	69
176	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693.	0.5	119
177	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1702-1705.	0.5	109
178	Rheumatoid arthritis and falls: the influence of disease activity. <i>Rheumatology</i> , 2012, 51, 2051-2057.	0.9	59
179	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.5	82
180	Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2814-2823.	6.7	218

#	ARTICLE	IF	CITATIONS
181	Comparative effectiveness and safety of biological treatment options after tumour necrosis factor $\hat{\pm}$ inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1303-1308.	0.5	108
182	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 235-243.	3.5	86
183	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 404-413.	0.5	657
184	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258.	2.0	32
185	Interleukin $\hat{\epsilon}$ 6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute $\hat{\epsilon}$ phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52.	6.7	141
186	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
187	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711.	6.7	122
188	Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10. <i>Journal of Rheumatology</i> , 2011, 38, 1452-1457.	1.0	84
189	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
190	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388.	0.9	109
191	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1631-1640.	0.5	63
192	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980.	0.5	54
193	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739.	0.5	159
194	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.5	71
195	Evaluation and outcomes of patients with rheumatoid arthritis. , 2011, , 941-954.e1.		1
196	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
197	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Arthritis and Rheumatism</i> , 2010, 62, 2569-2581.	6.7	6,781
198	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.5	203

#	ARTICLE	IF	CITATIONS
199	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541.	0.5	117
200	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 546-549.	0.5	76
201	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578.	0.5	47
202	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 964-975.	0.5	1,429
203	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.5	274
204	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.5	152
205	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 995-1003.	0.5	122
206	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064.	0.5	95
207	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1580-1588.	0.5	2,994
208	Treating rheumatoid arthritis to target: recommendations of an international task force. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 631-637.	0.5	1,711
209	Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology</i> , 2009, 48, 1575-1580.	0.9	79
210	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121.	0.9	198
211	Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 41.	0.8	35
212	The use of data from early arthritis clinics for clinical research. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 117-123.	1.4	10
213	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. <i>Arthritis and Rheumatism</i> , 2009, 60, 1242-1249.	6.7	127
214	The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care. <i>Rheumatic Disease Clinics of North America</i> , 2009, 35, 759-772.	0.8	39
215	Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. <i>Arthritis Research and Therapy</i> , 2009, 11, 112.	1.6	11
216	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 204.	1.6	56

#	ARTICLE	IF	CITATIONS
217	Outcome Measurement in Rheumatoid Arthritis: Disease Activity. , 2009, , 225-230.		2
218	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. Arthritis and Rheumatism, 2008, 58, 2622-2631.	6.7	46
219	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. Arthritis Research and Therapy, 2008, 10, 208.	1.6	69
220	Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). International Immunology, 2008, 20, 861-868.	1.8	188
221	Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Annals of the Rheumatic Diseases, 2008, 67, 238-243.	0.5	71
222	Is computer-assisted management necessary for patients with early rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2008, 4, 338-339.	3.2	0
223	Monitoring disease activity in rheumatoid arthritis: an imperative. Future Rheumatology, 2008, 3, 99-102.	0.2	1
224	Activity assessments in rheumatoid arthritis. Current Opinion in Rheumatology, 2008, 20, 306-313.	2.0	32
225	The health assessment questionnaire in routine clinical practice. Nature Clinical Practice Rheumatology, 2007, 3, 122-123.	3.2	1
226	Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. Annals of the Rheumatic Diseases, 2007, 66, 1284-1288.	0.5	87
227	New therapies for treatment of rheumatoid arthritis. Lancet, The, 2007, 370, 1861-1874.	6.3	859
228	Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. Arthritis Research and Therapy, 2007, 9, R72.	1.6	39
229	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. Arthritis and Rheumatism, 2007, 56, 3226-3235.	6.7	225
230	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Practice and Research in Clinical Rheumatology, 2007, 21, 663-675.	1.4	134
231	Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?. Arthritis Research and Therapy, 2006, 8, 102.	1.6	13
232	The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2006, 32, 9-44.	0.8	124
233	Pre-arthritis: a concept whose time has come. Future Rheumatology, 2006, 1, 1-4.	0.2	10
234	Early rheumatoid arthritis. Current Opinion in Rheumatology, 2006, 18, 282-288.	2.0	36

#	ARTICLE	IF	CITATIONS
235	The American College of Rheumatology N (ACR-N) debate: Going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , 2006, 54, 377-378.	6.7	13
236	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006, 54, 2784-2792.	6.7	241
237	Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 239-248.	2.9	67
238	Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 163-177.	1.4	74
239	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. <i>Arthritis and Rheumatism</i> , 2005, 52, 2625-2636.	6.7	428
240	Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2975-2983.	6.7	77
241	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3333-3336.	6.7	46
242	Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2005, 111, 204-211.	1.6	265
243	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. <i>Arthritis Research</i> , 2005, 7, R796.	2.0	838
244	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	1.0	132
245	The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S100-8.	0.4	417
246	Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1269-1275.	0.5	50
247	Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics. <i>Current Rheumatology Reports</i> , 2003, 5, 409-412.	2.1	7
248	Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002, 29, 1631-8.	1.0	83